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Since Knudson’s (1993) so-called two-hit hypothesis has
been shown to explain the origin of many different can-
cers with a dominant pattern of inheritance, the term
“loss of heterozygosity” (“LOH”) has acquired new and
increased significance with regard to malignancy. In this
article, however, I discuss the implications of recent find-
ings regarding the frequency, nature, and consequences
of LOH in normal somatic cells in vivo. I also will pro-
pose a broad operational definition of LOH, since the
term has been used inconsistently in the literature,
mostly in connection with cancers, and often inter-
changeably with terms such as “allelic imbalance” and
“reduction to homozygosity.”
The Genetics of Somatic Cells Mandates a Broad
Definition of LOH
In strict molecular terms, a locus is heterozygous
whenever each allele has a different DNA sequence.
Classic germ-line transmission genetics defines dominant
and recessive alleles by the phenotypic consequences of
each (e.g., the expression of a dominant, a recessive, or
a codominant phenotype) and zygosity by the various
pairings of alleles. However, with regard to so-called
heritable cancers, tumor-suppressor genes (TSGs), and
the two-hit hypothesis, LOH has been defined most fre-
quently in functional terms. In the somatic cells of an
individual at high risk for an inherited cancer, there is
one functionally inactive tumor-suppressor allele of
germ-line origin (the first so-called hit) and one normal
allele encoding a functional gene product. Most often,
the functionally inactive familial allele originates as a
consequence of intragenic point mutation, but other mu-
tational mechanisms may apply. The second hit is a sub-
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sequent somatic alteration (or mutation, in the broadest
sense) in the remaining normal allele, and its absolute
certainty of occurrence causes the trait (the germ-line
mutation) to appear to exhibit dominant familial inher-
itance. Actually, the apparent dominance results from
the fact that the number of cells at risk in a particular
tissue (e.g., retinoblast cells in retinoblastoma) is suffi-
cient to ensure that at least one cell will undergo a mu-
tation inactivating the second allele, given the known
rate of allelic mutation (Knudson 1993). This so-called
LOH results in the cellular absence of functional TSG
product and in the growth of that cell into a tumor, as
a consequence of cell-cycle deregulation (Levine 1997),
defective DNA repair, or altered cell-to-cell communi-
cation (Kinzler and Vogelstein 1996), which are phe-
notypes that are actually cellular recessives (e.g., re-
quiring both alleles to be inactivated). Interestingly, the
stochastic nature of somatic mutation predicts the in-
trafamilial variation in the age at which a primary tumor
occurs, despite the fact that all individuals within a fam-
ily carry the same germ-line mutation.
LOH, or loss of the normal, functional allele at a
heterozygous locus, may arise by any of several mech-
anisms. It may be a consequence of a multilocus chro-
mosomal event, such as deletion, mitotic recombination
(MR), or nondisjunctional chromosome loss with or
without reduplication; a locus-restricted event, such as
gene conversion or point mutation; or even an epigenetic
allelic inactivation (Cappione et al. 1997). Thus, the lo-
cus may become (1) homozygous through MR, gene con-
version, or chromosome loss with reduplication, (2)
hemizygous through deletion or chromosome loss with-
out reduplication, or (3) compound heterozygous
through the introduction of a different point mutation
in the second allele or (4) may remain heterozygous, in
terms of the DNA nucleotide sequence, if one allele is
inactivated epigenetically. In this review, I will use the
term “LOH” in a broad sense, to indicate the loss of
the functional gene product encoded by a particular lo-
cus. Likewise, I will use the term “mutation” in the
broadest sense, to describe any of the above events that
result in the expression of a trait that is a cellular re-
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cessive. One should bear in mind, however, that LOH
at a heterozygous locus also can lead to a homozygous
dominant genotype if the recessive allele is lost, although
this outcome is usually undetectable because it produces
no obvious change in phenotype. The differences be-
tween the genetics of germ-line and of somatic cells man-
date this broader, more functionally based definition of
LOH.
LOH in Normal Somatic Cells In Vivo
LOH at loci such as RB1, WT1, or TP53 clearly has
been demonstrated to be a key event in retinoblastoma,
Wilms tumor, or Li-Fraumeni syndrome, respectively
(Knudson 1993). In general, however, LOH is observed
for as many as one-half the chromosomes in a tumor
cell, some of which are not known to bear TSGs (Kinzler
and Vogelstein 1997). Although these so-called second-
ary regions of LOH may incidentally harbor TSGs that
contribute to malignancy, it is most likely that they arise
as a consequence of general chromosome instability in
advanced tumors (Kinzler and Vogelstein 1997). It may
be the case, for example, that absence of the normal
TP53 gene product, which is observed in more than one-
half of tumors, produces significant genomic instability
(Levine 1997). In any case, by the time that LOH is
observed in a tumor, its cells have undergone selection
for greater growth deregulation, as well as for other
traits that increase tumorigenicity (Kinzler and Vogel-
stein 1996). Clearly, if one is to observe primary LOH
under circumstances in which secondary genetic changes
favoring increased genomic instability have yet to occur,
one must examine LOH in completely normal cells.
Thus, one should define a human system in which LOH
can be studied in detail at both the phenotypic and the
molecular levels in normal cells of individuals without
premalignant conditions. Having satisfied these condi-
tions for a human model (Gupta et al. 1997a), we es-
tablished a similar mouse model that ultimately would
allow the introduction of genetic and of environmental
variables, in order to test their effects on LOH (Stam-
brook et al. 1996; C. Shao and J. A. Tischfield, unpub-
lished data).
The adenine phosphoribosyltransferase (APRT) locus
is an ideal surrogate marker for LOH studies (Stam-
brook et al. 1996). Profound autosomal recessive APRT
deficiency frequently manifests as 2,8-dihydroxyadenine
nephrolithiasis, in humans (Simmonds et al. 1997) and
in knockout mice (Engle et al. 1996). Human and mouse
APRT genes are located near the telomeres of human
chromosome 16 and of mouse chromosome 8, respec-
tively (Ceci 1996; Simmonds et al. 1997). Thus, prox-
imal chromosomal events such as MR or translocation
may produce changes in the linkage relationships be-
tween syntenic markers and specific APRT alleles. APRT
is expressed in all tissues, and the human and mouse
APRT genes are both well studied and similar. Further-
more, germ-line or somatic mutations in a large number
of codons have been shown to inactivate APRT (Sim-
monds et al. 1997). Most importantly, loss of cellular
APRT activity has little or no direct effect on cellular
viability and produces a selectable phenotype that is
manifested as resistance to toxic adenine analogs such
as 2,6-diaminopurine (DAP) (Tischfield and Ruddle
1974). Thus, somatic LOH at a heterozygous APRT lo-
cus, where one allele is inactivated as a consequence of
germ-line mutation, may produce cells without APRT
activity. These can be selected and clonally expanded by
growth in a medium containing DAP.
Studies of human APRT deficiency identified obligate
heterozygotes with known germ-line mutations. Periph-
eral blood T cells from four such heterozygotes were
cultured in DAP medium, immediately following veni-
puncture. The half-life of cellular APRT activity is long
enough so that only cells that had undergone LOH in
vivo at a much earlier time would grow in DAP. The
observed frequency of DAP-resistant T-cell clones, cor-
rected for cloning efficiency, was from to52 # 10
, for the four heterozgotes. Eighty clones515 # 10
from two heterozygotes were analyzed, of which at least
75 were determined to be of independent origin, by T
cell–receptor restriction-fragment patterns. A total of 61
clones (76%) exhibited LOH for APRT, as well as var-
iable LOH for flanking polymorphic simple-sequence re-
peats (SSRs) spaced along the entire length of 16q. In
all the clones from informative individuals, LOH ap-
peared to begin at some variable point proximal to
APRT and to extend through APRT and an even more
telomeric SSR marker. Conventional and FISH analyses
of 10 of these clones showed a normal diploid karyotype,
whereas 9 of the 10 clones showed two copies of APRT,
with one clone the apparent result of an interstitial de-
letion of the normal allele. With the exception of the
data for the latter clone and for one other, these data
are consistent only with MR as the mechanism of LOH
in this largest group of clones. In one other clone, LOH
extended through SSRs on 16p, suggesting chromosome
loss or major translocation. Somatic point mutation in
APRT was demonstrated definitively in 13 of 19 clones
in which there were two distinct APRT alleles (Gupta
et al. 1997a). The revised definition of LOH based on
the loss of functional gene product includes this latter
group.
To obviate the possibility that T cells but not most
other cell types exhibit high rates of MR due to the
existence of enzyme systems for T cell–specific recom-
bination processes (Jackson and Jeggo 1995), we de-
veloped a heterozygous, primary-fibroblast, mouse LOH
model based on our Aprt knockout mouse (Engle et al.
1996). Heterozygous (Aprtneo/Aprt), dissociated, mouse
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ear fibroblasts from strain 129#C3H hybrid mice were
plated immediately into culture medium containing
DAP. The incidence of DAP-resistant cell colonies was
∼104 (corrected for cloning efficiency), and 90% of the
colonies showed loss of the wild-type Aprt allele. Cells
with Aprt loss also exhibited variable loss of cis chro-
mosomal SSRs, which extended uninterrupted through
the most telomeric SSR. Analyses of fibroblast chro-
mosomes indicated euploid karyotypes (C. Shao and J.
A. Tischfield, unpublished data). These data are most
compatible with MR as the major mechanism for high-
frequency LOH in mouse primary fibroblasts and are
quantitatively and qualitatively quite similar to the data
from human T cells. More recently, we also have made
similar preliminary observations for mouse T cells (L.
Liang and J. A. Tischfield, unpublished data).
Thus, both the mouse and the human data determined
by use of APRT as a marker support the notion that
LOH is relatively frequent (from 104 to 105) in normal
cells in vivo and that it mainly is due to MR. Earlier
indirect evidence for MR in vivo has been reviewed by
Morley (1991), although none of the cell/marker systems
previously used allowed for the unambiguous pheno-
typic, molecular, and cytogenetic analyses that are pos-
sible with APRT. For example, LOH frequency at the
heterozygous HLA-A2 locus has been reported to be
between (Morley 1991) and 104 (Kushiro52.7 # 10
et al. 1992), and at least 30% of the LOH appears to
be due to MR. The frequency of LOH in vivo and the
extent to which it is a consequence of MR or of point
mutation depend on a number of variables, such as the
size of the mutational target and its distance from the
centromere. Perhaps some of the differences between the
data from the HLA-A2 and APRT loci stem from their
different sizes and from the fact that HLA-A2 is much
closer to its centromere than APRT is to its centromere.
LOH in Cell Lines, Tumors, and Other Diseases
LOH at HLA-A2 in lymphoblastoid permanent cell
lines was observed at a frequency similar to that ob-
served for normal cells in vivo, but the majority of
events, rather than the minority, appeared to involve
recombination (de Nooij–van Dalen et al. 1997). DAP
selection of cultured human lymphoblasts showed either
(1) LOH beginning primarily at one point or chromo-
some translocations (Smith and Grosovsky 1993) or (2)
high frequencies ofAPRT deletion (Fujimori et al. 1992).
DAP selection of cultured fibrosarcoma cells showed a
broad range of molecular and chromosomal mechanisms
for LOH that were not observed in vivo, such as chro-
mosome loss and translocation (Shao et al. 1996; Gupta
et al. 1997b). Recently, a comparison of mismatch-re-
pair-competent and -incompetent human colorectal car-
cinoma cell lines revealed profound quantitative and
qualitative differences in APRT LOH (broad definition),
highlighting the notion that the nature of LOH is de-
pendent on the cellular genotype (Phear et al. 1996).
Perhaps LOH in some cell lines more closely resembles
that observed in tumors and should be interpreted with
caution, since it is not possible to know the status of all
mismatch-repair and similar types of genes in any par-
ticular cell line or tumor. Thus, much of the literature
on LOH in cell lines and in tumors may not directly
speak to events of primary LOH in normal cells in vivo.
Rather, the literature is likely to reflect the events in
tumor progression that produce increasing genomic in-
stability (Kinzler and Vogelstein 1996), which in turn
alters the nature of LOH and may include the evolution
of mutator phenotypes that accelerate the rate of further
genetic change (Loeb 1991).
In addition to the well-studied inherited cancers, LOH
also has been implicated in several diseases manifesting
hyperplasia, as discussed by Qian and Germino (1997
[in this issue]). For each disease, it remains to be deter-
mined whether normal cellular mechanisms of LOH ap-
ply or whether the genotype predisposes to LOH. Al-
ternatively, in some diseases LOH merely may be an
incidental finding, perhaps associated with hyperplasia.
The Role of MR in Vertebrates
Homologous recombination (HR), manifested as ei-
ther MR or gene conversion, is well established as the
major mechanism for the repair of double-strand breaks
(DSBs) in yeast (Shinohara and Ogawa 1995). In con-
trast, it was thought that DSBs in vertebrates were re-
paired by the direct joining of DNA ends, mediated by
DNA-dependent protein kinase, without reliance on se-
quence homology (Jackson and Jeggo 1995). Recent ev-
idence indicates, however, that HR also plays a highly
significant role in vertebrate DNA repair. Mouse and
chicken cells with defects in RAD54, a member of the
RAD52 epistasis group, which mediates HR in yeast,
show reduced HR and sensitivity to ionizing radiation
and to certain mutagens. These data highlight the con-
tributions of HR to normal repair in these species (Bez-
zubova et al. 1997; Essers et al. 1997). Also, there is
evidence that certain point mutagens stimulate the repair
of mutations by inducing HR (Sengstag 1997), and HR
in mouse embryonic stem cells is increased by at least
two orders of magnitude, after induction of a specific
chromosomal DSB (Moynahan and Jasin 1997). Cu-
mulatively, these data indicate that HR is an inducible
process that mediates some vertebrate DNA repair, per-
haps in a manner similar to that of HR in yeast. It is
not clear whether HR is distinct from or complementary
to the other repair process, which allows direct joining
of the ends of DSBs.
HR in mammals has been viewed as a process with
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mainly negative consequences, because of its role in the
production of homozygosity for mutant TSGs—an event
that, for over a decade, has been known to cause cancer
(Knudson 1993). Recent speculation is that vertebrate
DNA repair by direct joining of DSB ends evolved be-
cause it bypassed the negative effects of LOH that were
caused by HR-mediated repair (Moynahan and Jasin
1997). However, direct joining of DSB ends also can
have occasional negative consequences. Direct joining of
DSB ends is impaired in radiosensitive cell mutants
(Jackson and Jeggo 1995), and errors in the process pro-
duce various chromosomal aberrations, the frequencies
of which are increased by ionizing radiation (Lloyd and
Edwards 1983).
Although HR in mammals may be, on one hand,
merely a reflection of ongoing repair processes, one can
speculate about additional beneficial roles, such as the
correction of mutant phenotypes in heterozygotes (De
Sepulveda et al. 1995; Jonkman et al. 1997) or the pro-
motion of homozygosity for certain normal alleles. With
regard to the latter, embryonic ontogeny may be more
demanding than adult homeostasis, in requiring the
functional product of both alleles of certain genes (e.g.,
a morphogen or a receptor whose proper action depends
on its concentration). Thus, heterozygosity at a partic-
ular locus in an embryonic cell might reduce its fitness.
One also could postulate that embryonic cells might have
rates of HR higher than those of adult cells. Thus, HR
and MR in particular could establish homozygosity for
key normal alleles, in a significant fraction of embryonic
cells. This subset of cells, which are homozygous at cer-
tain loci, might have a selective advantage that would
allow them to make a disproportionate contribution to
the development of the embryo. However, LOH of large
chromosomal segments, owing to MR, also may unmask
a recessive phenotype(s) that is lethal to cells. This is not
likely to be critical because, after the death of a fraction
of the cells in early embryos, compensatory growth of
the remaining viable cells allows for normal develop-
ment. Thus, the benefits of homozygosity at some points
in ontogeny may outweigh the risks of LOH in the adult,
in terms of species survival.
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